Compute the Number Needed to Treat (NNT), Absolute Risk Reduction (ARR), Relative Risk Reduction (RRR),control and experimental event rates from clinical trial data. Get 95% confidence intervals and evidence-based interpretation.
The Number Needed to Treat (NNT) is a clinical epidemiology metric that estimates how many patients must receive a treatment for one additional patient to experience a beneficial outcome (or avoid an adverse event) compared with a control intervention. It is one of the most intuitive and clinically relevant measures of treatment effect size, widely used in evidence-based medicine (EBM), systematic reviews, and clinical guidelines.
The NNT is calculated as the reciprocal of the Absolute Risk Reduction (ARR):
A lower NNT indicates a more effective treatment. For example, an NNT of 5 means that treating 5 patients with the intervention will, on average, result in one additional favorable outcome compared with the control. Conversely, an NNT of 50 implies a modest benefit that may only be clinically relevant in low-risk populations or over long time horizons.
The NNT is valued in clinical practice because it translates statistical effects into a concrete number that can be discussed with patients. It helps answer the question: “How many patients do I need to treat with this drug to see one success?” This patient-oriented framing supports shared decision‑making and risk communication.
However, interpretation must consider the baseline risk (control event rate). The same NNT can arise from very different absolute risks. For instance, an NNT of 10 from a CER of 20% and EER of 10% is clinically very different from an NNT of 10 derived from a CER of 2% and EER of 1%. The former is a high‑risk population where the benefit is more tangible; the latter is a low‑risk population where the benefit is marginal.
Clinical guidelines often provide thresholds: NNT ≤ 5 is considered highly effective, 6–10 effective, 11–20 moderate, and > 20 limited. These thresholds are context‑dependent and should be adjusted for disease severity, treatment cost, side‑effects, and patient preferences.
Communicating NNT with patients: When discussing the NNT with a patient, it is often helpful to frame it in terms of time and absolute risk. For example, an NNT of 20 over 5 years can be expressed as: “Out of 20 patients like you who take this medication for 5 years, we expect 1 to avoid the event who would have had it otherwise, while 19 will not see a direct benefit from the treatment—though they may still receive other preventive effects.” This balanced communication fosters shared decision‑making and aligns with the principles of patient‑centered care.
This tool implements the standard NNT formula using data from a two‑arm clinical trial or cohort study. You provide the number of events and total participants in both the control and treatment groups. The calculator then computes:
The confidence intervals are computed using the standard error of the risk difference:
The 95% CI for ARR is: ARR ± 1.96 · SE(ARR). The 95% CI for NNT is obtained by taking the reciprocal of the ARR confidence limits, provided the interval does not include zero. If the ARR CI crosses zero, the NNT CI is reported as discontinuous (infinite).
All calculations follow the recommendations of the Cochrane Collaboration and the BMJ Evidence-Based Medicine working group.
A large randomized trial evaluated a new statin for primary prevention of myocardial infarction. In the control group (placebo), 120 out of 1000 patients experienced a major cardiac event over 5 years. In the treatment group, 80 out of 1000 patients experienced an event.
Results: CER = 12.0%, EER = 8.0%, ARR = 4.0%, RRR = 33.3%, NNT = 25. This means that treating 25 patients with the statin for 5 years prevents one additional cardiac event. The 95% CI for NNT ranges from 17 to 50, indicating moderate precision.
Clinical takeaway: In a primary prevention setting with moderate baseline risk, an NNT of 25 is considered clinically meaningful, especially given the low cost and favourable safety profile of statins.
A phase 3 COVID‑19 vaccine trial enrolled 2000 participants in each arm. In the placebo group, 50 participants developed symptomatic infection. In the vaccine group, only 10 developed infection.
Results: CER = 2.5%, EER = 0.5%, ARR = 2.0%, RRR = 80%, NNT = 50. Treating 50 individuals with the vaccine prevents one case of symptomatic infection.
Clinical takeaway: Even though the RRR is high (80%), the low baseline incidence means the NNT is 50. In a pandemic context with high transmission risk, this NNT is highly favourable at the population level, but the individual benefit is modest in absolute terms.
A bisphosphonate trial for fracture prevention enrolled 600 post‑menopausal women in each arm. In the control group, 90 women sustained a fracture over 3 years. In the treatment group, 60 women sustained a fracture.
Results: CER = 15.0%, EER = 10.0%, ARR = 5.0%, RRR = 33.3%, NNT = 20. Treating 20 women for 3 years prevents one additional fracture.
Clinical takeaway: An NNT of 20 is typical for fracture prevention in high‑risk populations. The decision to treat should balance this benefit against potential side‑effects (e.g., atypical femoral fractures, osteonecrosis of the jaw).
While the NNT is a powerful communication tool, it has several important limitations that clinicians and researchers must recognise:
| Metric | Definition | Interpretation | Key Advantage |
|---|---|---|---|
| NNT | 1 / ARR | Number of patients to treat for one additional benefit | Intuitive for clinicians and patients |
| ARR | CER − EER | Absolute difference in event rates | Direct measure of clinical benefit |
| RRR | ARR / CER | Relative reduction in event rate | Comparable across studies; often larger than ARR |
| Odds Ratio | (a/b) / (c/d) | Ratio of odds of event | Useful for case‑control studies |
| Hazard Ratio | HR = htreat / hcontrol | Time‑to‑event comparison | Accounts for censoring and time |